|
gptkbp:instanceOf
|
gptkb:psychotherapy
|
|
gptkbp:aimsTo
|
mental health disorders
|
|
gptkbp:associatedWith
|
gptkb:Stanislav_Grof
gptkb:Timothy_Leary
gptkb:Rick_Doblin
gptkb:Roland_Griffiths
|
|
gptkbp:benefit
|
spiritual experiences
improved mood
reduced symptoms
|
|
gptkbp:contraindication
|
schizophrenia
psychosis
|
|
gptkbp:historicalPeriod
|
1950s
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Psychedelic therapy
|
|
gptkbp:involves
|
guided sessions
integration therapy
preparation sessions
|
|
gptkbp:legalStatus
|
varies by country
|
|
gptkbp:regulates
|
Australia (limited clinical use)
Canada (limited research settings)
United States (limited research settings)
|
|
gptkbp:relatedTo
|
gptkb:psychotherapy
psychedelic research
pharmacotherapy
|
|
gptkbp:requires
|
trained therapists
medical supervision
|
|
gptkbp:restrictedSubstance
|
gptkb:ketamine
gptkb:ayahuasca
gptkb:MDMA
psilocybin
LSD
|
|
gptkbp:riskFactor
|
psychological distress
anxiety
hallucinations
|
|
gptkbp:studiedBy
|
gptkb:Imperial_College_London
gptkb:Johns_Hopkins_University
gptkb:MAPS_(Multidisciplinary_Association_for_Psychedelic_Studies)
|
|
gptkbp:subjectOf
|
gptkb:media
clinical trials
scientific research
|
|
gptkbp:treatment
|
experimental
adjunct to psychotherapy
assisted psychotherapy
|
|
gptkbp:usedFor
|
gptkb:depression
addiction
anxiety
PTSD
end-of-life distress
|
|
gptkbp:uses
|
psychedelic substances
|
|
gptkbp:bfsParent
|
gptkb:Hallucinogens
|
|
gptkbp:bfsLayer
|
7
|